hotspot -WSS

hotspot

author：leisure time 2025-09-28 02:29:34 - browse：5645

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Senate committee scrutinizes Medicare Advantage brokers

focus

WSS

Nobel honors Karikó and Weissman's enduring partnership

UnitedHealth’s board chair also owns a personal investment firm

Lawmakers consider Medicare pay reforms for doctors

STAT Summit: Biotech founders on deal

FDA gives detailed accounting of AI

UnitedHealth’s board chair also owns a personal investment firm

leisure time

hotspot

explore

Dobbs anniversary: the lost opportunity of abortion as health care

What we owe ALS patients — and why one company fell short

The cancer drug shortage isn’t new — and neither are the solutions

With Roe v Wade overturned, abortion providers work to adapt

Malaria cases in Florida and Texas: Here’s what you need to know

HHS leader on health, climate change and biopharma emissions

New air purifier tech could be key to improving indoor air quality

CDC picks Alphabet's Verily for wasterwater surveillance contract

Peter Hotez and the public health issue of online harassment

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

Will Ozempic

First Opinion Podcast: Long Covid needs a new approach

6 solutions to address cancer drug shortages and others

STAT Summit: Michael J. Fox on progress in Parkinson's research

Will Ozempic

STAT Summit: GSK CEO on pharma giant's new direction

leisure time

focus

knowledge

entertainment